Document is current
Any future updates will be listed below
-
Authors
Ross, Robert https://orcid.org/0000-0001-6875-785X
Neeland, Ian J.
Yamashita, Shizuya
Shai, Iris
Seidell, Jaap
Magni, Paolo
Santos, Raul D.
Arsenault, Benoit https://orcid.org/0000-0003-2240-8456
Cuevas, Ada
Hu, Frank B.
Griffin, Bruce A.
Zambon, Alberto
Barter, Philip
Fruchart, Jean-Charles
Eckel, Robert H.
Matsuzawa, Yuji
Després, Jean-Pierre https://orcid.org/0000-0002-5193-583X
- License Information
-
More Information
Article History
Accepted: 5 December 2019
First Online: 4 February 2020
Competing interests
: I.J.N. reports receiving fees for consulting and serving on the advisory board from Boehringer Ingelheim/Lilly Alliance and AMRA Medical and a research grant from Novo Nordisk. F.B.H. reports receiving speaker fees from Metagenics and Standard Process and a research grant from California Walnut Commission. R.D.S. reports receiving consulting and speaker fess from Amgen, Astra Zeneca, Akcea, Biolab, Esperion, Kowa, Merck, MSD, Novo Nordisk, Sanofi Regeneron, Akcea, Kowa and Esperion. S.Y. reports grants and personal fees from Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Bayer Yakuhin, Ltd., MSD K.K., Takeda Pharmaceutical Company, Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Astellas Pharma Inc., Daiichi-Sankyo Company, Ltd., Astra Zeneka K.K. and Kaken Pharmaceutical Co., Ltd.; grants from Kyowa Medex Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., National Institute of Biomedical Innovation, Hayashibara Co., Ltd., Teijin Pharma Limited, Kissei and Mochida Pharmaceutical Company, Ltd.; and personal fees from Ono Pharmaceutical Company, Ltd., Skylight Biotec, Inc., Pfizer, Astellas Amgen, Sanofi and Aegerion. S.Y. also has patents issued with Fujirebio and Kyowa Medex Co., Ltd. issued. R.H.E. reports his role as a scientific adviser for PROMINENT (Kowa Company Ltd.) and being on the advisory committees for Novo Nordisk and Sanofi/Regeneron. The remaining authors declare no competing interests.
